Skip to main content

Table 1 demographic and clinical features of the patients enrolled in this study

From: Analysis of long term CD4+CD25highCD127- T-reg cells kinetics in peripheral blood of lung transplant recipients

 

N° of patients = 137

Mean age at Tx (years ± SD)

46.1 ± 12.86

Sex (M:F)

91:46

Lenght of post-Tx follow-up (months/range, median)

105.9 / 6.7–310.5

Tx Indications

 Emphysema / Alpha1 antitrypsin Deficiency

27

 Primary graft disfunction

4

 Bronchiectasis / Cystic Fibrosis

26

 Interstitial lung disease

52

 Pulmonary hypertension / Ebstein’s disease/Eisenmenger Syndrome / Mounier-Kuhn Syndrome

25

 Rare pulmonary conditions

3

Type of Tx

 Single lung Tx

46

 Double lung Tx

83

 Heart and Lung Tx

8

Immunosuppression therapy

 Cyclosporine

23

 Tacrolimus

119

 Azathioprine

15

 Mycophenolate mofetil

88

 Rapamycin

37

 Prednisone

137

 Extracorporeal photopheresis (ever)

39

 Azitromycin (ever)

98

 

Total of determination = 1943

 Stable

796

 CLAD

1147

 BOS

838

 RAS

309

 BOS 0p

320

 CLAD 1

412

 CLAD 2

169

 CLAD 3

246

  1. CLAD chronic lung allograft dysfunction, BOS bronchiolitis obliterans syndrome, RAS restrictive allograft syndrome. BOS 0p according to published guidelines [6, 30,31,32] CLAD 1: includes both BOS1 and RAS patients with FEV1 80–65% + FVC < 80%; CLAD 2: includes both BOS2 and RAS patients with FEV1 64–50% + FVC < 80%; CLAD 3: includes both BOS3 and RAS patients with FEV1 < 50% + FVC < 80%